Compare stocks

Gubra A/S is a biotechnology company focused on the research and development of peptide-based therapeutics and innovative technologies for the treatment of obesity, diabetes, and related metabolic disorders. The company's core business includes providing preclinical contract research services with an emphasis on metabolic and fibrotic diseases. Gubra is headquartered in Hørsholm, Denmark. The company emphasizes its expertise in translational models and histology, supporting its unique strategic positioning in the biotech contract research space. By integrating computational biology with experimental data, Gubra aims to deliver comprehensive insights that aid in drug discovery and development.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.